Cover Image
市場調查報告書

Orexin第一型受體:開發平台分析

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 359824
出版日期 內容資訊 英文 57 Pages
訂單完成後即時交付
價格
Back to Top
Orexin第一型受體:開發平台分析 Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Pipeline Review, H2 2017
出版日期: 2017年10月31日 內容資訊: 英文 57 Pages
簡介

本報告提供以Orexin第一型受體為標的的藥物適應症,開發階段,作用機制,給藥途徑及各分子類型分析,藥物的藥理作用之相關記述,並彙整迄今的研究開發趨勢,最新的新聞和發表,藥物的主要開發企業概要,休止/中止的計劃等資訊。

簡介

  • 調查範圍

Orexin第一型受體概要

治療藥的開發

Orexin第一型受體:開發中的產品 - 各開發階段

Orexin第一型受體:開發中的產品 - 治療範圍別

Orexin第一型受體:開發中的產品 - 各適應症

Orexin第一型受體:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

Orexin第一型受體:企業開發中的產品

Orexin第一型受體:治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

Orexin第一型受體的治療藥開發企業

  • C4X Discovery Holdings PLC
  • Eisai
  • Hager Biosciences, LLC
  • Heptares Therapeutics Limited
  • Merck & Co., Inc.

藥物簡介

Orexin第一型受體:暫停中的計劃

Orexin第一型受體:開發中止的產品

Orexin第一型受體:主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1098TDB

Summary:

According to the recently published report 'Orexin Receptor Type 1 - Pipeline Review, H2 2017'; Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) pipeline Target constitutes close to 14 molecules. Out of which approximately 14 molecules are developed by Companies.

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Orexin receptor type 1 (Ox1R or OX1) is a protein that is encoded by the HCRTR1 gene. The orexin 1 receptor (OX1) is a G-protein coupled receptor that is highly expressed in projections from the lateral hypothalamus and is involved in the regulation of feeding behavior. OX1 selectively binds the orexin-A neuropeptide.

The report 'Orexin Receptor Type 1 - Pipeline Review, H2 2017' outlays comprehensive information on the Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 7 and 3 respectively. Report covers products from therapy areas Central Nervous System which include indications Insomnia, Nicotine Addiction, Alcohol Addiction, Anxiety Disorders, Binge Eating Disorder, Drug Addiction, Addiction, Narcolepsy, Panic Disorders, Pathological Gambling and Sleep Disorders.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1)
  • The report reviews Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Overview
    • Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Companies Involved in Therapeutics Development
    • C4X Discovery Holdings PLC
    • Chronos Therapeutics Ltd
    • Eisai Co Ltd
    • Hager Biosciences LLC
    • Heptares Therapeutics Ltd
    • Idorsia Ltd
    • Johnson & Johnson
    • Merck & Co Inc
    • OptiNose US Inc
    • Yangtze River Pharmaceutical Group
  • Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Drug Profiles
    • ACT-539313 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACT-541468 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CTDP-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DORA-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EORA-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HTL-6641 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-3215 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lemborexant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OPN-021 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize CRF-R1 and OREXIN-1 for Nicotine Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Orexin 1 and 2 Receptors for Insomnia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Orexin-1 Receptor for Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • suvorexant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Dormant Products
  • Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Discontinued Products
  • Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Product Development Milestones
    • Featured News & Press Releases
      • Jul 28, 2017: ACT-541468 (DORA) meets primary endpoint in Phase 2 program in adult and elderly patients with insomnia
      • Oct 28, 2016: Eisai To Initiate Phase II Clinical Study Of Dual Orexin Receptor Antagonist Lemborexant In Patients With Irregular Sleep-Wake Rhythm Disorder And Dementia
      • Jul 07, 2016: Actelion To Enter Phase II Clinical Development With New Dual Orexin Receptor Antagonist In Patients With Insomnia
      • Feb 01, 2016: OptiNose Announces Pipeline Project to Evaluate Nose-to-Brain Application of Bi-Directional Breath Powered Technology Selected for Norwegian Government Funding
      • May 20, 2015: Selection of drug candidate from Orexin-1 programme to treat stress-related addictive disorders and entry into pre-clinical development
      • Feb 03, 2015: Merck's Insomnia Medicine BELSOMRA (suvorexant) C-IV, the First and Only Orexin Receptor Antagonist, Now Available in the United States
      • Dec 10, 2014: Eisai Demonstrates Efficacy Of Investigational Dual Orexin Receptor Antagonist E2006 In Sleep Initiation And Maintenance
      • Nov 26, 2014: Merck announces launch of Berusomura tablets15mg/20mg in Japan
      • Aug 13, 2014: FDA Approves BELSOMRA for the Treatment of Insomnia
      • Jul 01, 2013: Merck Receives Complete Response Letter for Suvorexant, Merck's Investigational Medicine for Insomnia
      • May 22, 2013: Merck Wins FDA Panel Recommendation For Insomnia Drug Suvorexant At Lower Dose
      • May 20, 2013: Merck's Experimental Insomnia Drug Safe But May Carry Troublesome Side Effects, FDA Staff Says
      • Apr 03, 2013: Merck's Insomnia Drug Suvorexant Induces Sleep With Fewer Side Effects, Preclinical Study Shows
      • Nov 28, 2012: New Drug May Offer New Approach To Treating Insomnia, Study Finds
      • Nov 08, 2012: Merck Announces FDA Acceptance Of New Drug Application For Suvorexant
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by C4X Discovery Holdings PLC, H2 2017
  • Pipeline by Chronos Therapeutics Ltd, H2 2017
  • Pipeline by Eisai Co Ltd, H2 2017
  • Pipeline by Hager Biosciences LLC, H2 2017
  • Pipeline by Heptares Therapeutics Ltd, H2 2017
  • Pipeline by Idorsia Ltd, H2 2017
  • Pipeline by Johnson & Johnson, H2 2017
  • Pipeline by Merck & Co Inc, H2 2017
  • Pipeline by OptiNose US Inc, H2 2017
  • Pipeline by Yangtze River Pharmaceutical Group, H2 2017
  • Dormant Projects, H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top